Medtronic Reports Positive Real-World Data for Sphere-9 and PulseSelect Ablation Systems

Medtronic (MDT) reported positive results from two large real-world registries evaluating its Sphere-9 Catheter and PulseSelect Pulsed Field Ablation System in patients with heart rhythm disorders, presented at the Asia Pacific Heart Rhythm Society 2026 meeting. The APEX registry included 1,050 atrial fibrillation patients treated with the Sphere-9 catheter and Affera Mapping and Ablation System across 28 sites worldwide, reporting a 1.1% major complication rate with no cases of acute kidney injury, severe coronary spasm, or phrenic nerve injury. The REAL PULSE registry evaluated 1,160 patients treated with PulseSelect at 38 global sites, citing 100% acute procedural success and a 0.09% major complication rate. A separate European APEX analysis of 46 patients treated for ventricular tachycardia reported an 87% acute success rate and an estimated six-month freedom from recurrence of 75%. MDT closed Wednesday's trading at $93.03, down 1.69%, and was at $93.26 pre-market, up 0.25%. The stock has traded between $73.31 and $106.33 over the past year.